DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support

Information source: University of Zagreb
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Luteal Phase Defect

Intervention: Oral dydrogesterone (Drug); Crinone 8% gel (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Zagreb

Official(s) and/or principal investigator(s):
Jozo Tomic, M.D., Principal Investigator, Affiliation: Department of Human Reproduction, University Hospital Center Sisters of Mercy
Vlatka Tomic, M.D., Study Chair, Affiliation: Department of Human Reproduction, University Hospital Center Sisters of Mercy


The purpose of this study is to compare efficacy and tolerability of the dydrogesterone and the vaginal progesterone, used for luteal phase support. (Initial start date was January 2009 but not for patients' recruitment only for paper work, documents, team organization, statistical pre-work actions and to gain the official approval of Institutional Review Board. The recruitment started in October 2010 and continued until October 2013.)

Clinical Details

Official title: Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Ongoing pregnancy rate

Secondary outcome:

Number of participants with adverse events


Detailed description: The use of gonadotropin-releasing hormone (GnRH) agonists in the ovarian stimulation, which prevents a premature surge of luteal hormone (LH), ultimately leads to suppression of the pituitary gland and high levels of estrogen observed during induced cycles result in inhibiting effect on the implantation of human embryos. The luteal support in in-vitro-fertilization (IVF) cycles can be prolonged using human chorion gonadotropin(hCG) and/or progesterone. Since it has been noted that the use of hCG was related with higher risks of the onset of ovarian hyperstimulation syndrome (OHSS), progesterone is nowadays a product of choice in luteal support. Currently vaginal progesterone is widely used, since the classic oral progesterone results in low bioavailability and lower pregnancy rate and the intramuscular progesterone (IM-P) daily injections are painful and may cause abscesses, inflammatory reactions and local soreness. However, standard protocol for luteal phase support has not been established (i. e. optimal dosage, route or duration). Dydrogesterone is a retroprogesterone with good oral bioavailability. Oral administration is clear advantage, due to expected higher patient compliance and better tolerability than currently used vaginal or IM-P. We hypothesize that dydrogesterone has the same efficacy as vaginal progesterone but better tolerability due to less side effects.


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.


Inclusion Criteria:

- routine ovulation induction protocol with GnRH agonist

- less than three prior IVF cycles

- at least three aspirated oocytes

- BMI <35 kg/m2

- age <45 years

Exclusion Criteria:

- history of dysfunctional uterine bleeding

- acute urogenital disease

- recurrent miscarriage

- previous allergic reactions to a progesterone products

Locations and Contacts

University Hospital Center Sisters of Mercy, Zagreb 10000, Croatia
Additional Information

Starting date: October 2010
Last updated: January 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017